- Reuters•39 minutes ago
AstraZeneca's chief executive said on Thursday his company remained "very committed" to investment in Britain, despite challenges in the UK market. Drugmakers are concerned at low healthcare spending and limited use of new drugs in the National Health Service, which results in French and German patients being five times more likely to receive a newly launched medicine than those in Britain. Industry is also worried about the impact of the country's decision to leave the European Union, which has created significant regulatory uncertainty.
- The Wall Street Journal•6 hours ago
GlaxoSmithKline’s new boss Emma Walmsley plans to narrow the company’s drug research to focus only on the biggest opportunities.
- Reuters•19 hours ago
GlaxoSmithKline's new chief executive aims to improve returns in drug development, and wants fewer but bigger new medicine launches. In her first comments since taking over on April 1, Emma Walmsley, 47, said on Wednesday that her priority was the pharmaceuticals unit, where she wants commercial considerations to be given greater weight in early investment decisions. "We'd like to have probably fewer and more focused priorities, to have bigger launches," she told reporters, after announcing first-quarter results, adding this would involve tough choices and the closure of some research programmes.
GSK.L : Summary for GLAXOSMITHKLINE PLC ORD 25P - Yahoo Finance
GlaxoSmithKline plc (GSK.L)
LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
|Bid||1,548.00 x 175400|
|Ask||1,548.50 x 417900|
|Day's Range||1,543.15 - 1,567.00|
|52 Week Range||1,363.00 - 1,745.56|
|PE Ratio (TTM)||83.23|
|Dividend & Yield||1.01 (4.94%)|
|1y Target Est||N/A|